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Immunogenicity of standard and low 
dose vaccination using yeast-derived 
recombinant hepatitis B surface antigen 
in elderly volunteers 
S. de Rave *z, R.A. Heijtink*, M. Bakker-Bendik*, J. Boot* and S.W. Schalm* 
There is no conclusive vidence that age influences the response to vaccination against 
hepatitis B virus. We therefore studied the immunogenicity of  yeast-derived rHBsAg 
vaccine in elderly volunteers. The study was conducted in the outpatient clinics of an 
academic and a regional hospital, in a rural family practice and in an urban community 
centre. We recruited 112 healthy volunteers aged 59 years and over, to whom 10 or 20 #g 
yeast-derived HBsAg was given at O, 1 and 6 months. Anti-HBs titres were measured by 
radioimmunoassay t 2, 6 and 7 months. Responders and non-resffonders were compared 
using univariate non-parametric tests and multivariate logistic regression analysis. Of the 
116 subjects who volunteered to take part in the study, 106 vaccinees completed it. The 
percentage of subjects with an anti-HBs titre >~ 10 IU l-1 at 7 months was 60% (95% 
confidence interval: 51-70%; geometric mean titre: 253 IU l-1). Of the factors studied, 
i.e. setting, age, sex, alcohol consumption, current medication and vaccine dose, the use 
of medication at the time of the first vaccination was the only independent factor related 
to the response to vaccination, with a response rate of 78% (95% confidence interval: 
66-89%) in those without medication. In elderly subjects, the proportion with protective 
concentrations of  anti-HBs after vaccination with 10 or 20 #g yeast-derived recombinant 
HBsAg in a standard scheme is lower than in healthy adolescents. Within the older age 
group studied here, the use of medication, probably reflecting eneral health, is the only 
significant factor influencing the response to vaccination. 
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The development of plasma-derived hepatitis B virus 
(HBV) vaccines, succeeded by safe and efficacious 
recombinant HBsAg vaccines 1,has opened the way to 
mass vaccination against hepatitis B. Most candidates 
for hepatitis B vaccination are either infants or young 
adults. However, hepatitis B vaccination is also indicated 
for elderly subjects in high-risk groups. Among the risk 
factors are admission to chronic care facilities, chronic 
haemodialysis and visits to endemic areas. Some elderly 
health care workers also require hepatitis B vaccination. 
There are suggestions but no definite proof that the 
response to vaccination declines with advancing age, as 
has been described for the influenza virus 2. A negative 
effect of age on the response to hepatitis B vaccination 
in healthy volunteers 3"4, patients with Down's syndrome 5 
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and patients on chronic haemodialysis 6'~ has been 
reported. Plasma-derived vaccines were used in these 
studies. It is not clear whether there are other negative 
influences or whether the possible negative ffect of age 
can be overcome, for instance by the use of recombinant 
HBsAg vaccine or by increasing the dose of hepatitis B 
vaccine. We therefore compared the effect of 10 #g and 
20 #g yeast-derived recombinant HBsAg in a standard 
schedule with vaccinations at 0, 1 and 6 months in 112 
healthy elderly volunteers. The dose of 20#g is 
recommended and is probably above optimal in healthy 
adolescents 1. A dose of 10/zg was used for comparison 
because the effect of other factors, such as age and general 
health, were expected to be more readily discernible at 
this dose. 
PAT IENTS AND METHODS 
A total of 116 healthy volunteers aged 59 years and older 
were screened for inclusion in the study. Healthy was 
defined as being self-supporting and free of life- 
threatening disease. The number of men was 65. 
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Table 1 Indications for and types of medication in volunteers 
participating in the study on the immunogenicity of yeast-derived 
recombinant HBsAg in elderly subjects 
Number of 
Disorder Medication patients 
Cardiovascular Diuretics 15 
Aspirin 9 
Calcium entry blockers 8 
ACE inhibitors 8 
/~-adrenoreceptor blockers 5 
Others 8 
Gastrointestinal Antacids 13 
5-ASA 4 
Others 7 
Asthmatic Topical 6 
Systemic 2 
Endocrine Thyroid hormone 6 
Anti-thyroid 3 
Oral antidiabetic 7 
Insulin 4 
Miscellaneous Vitamins/iron/folic acid 7 
Analgesics/NSAIDs 5 
Others 17 
Total 134 
Note: Some patients used more than one prescription from the same 
category 
Exclusion criteria were the use of immunosuppressant 
drugs or anticoagulants. Informed consent was obtained 
in all cases. The study was conducted between February 
1989 and February 1992. Subjects were recruited in the 
outpatient clinics of an academic hospital and of a 
regional hospital, in rural family practice and in an urban 
community centre. The use of medication and alcohol 
was recorded. No medication was used by 51 patients, 
while the remaining 61 used 151 prescriptions (Table 1). 
The study was approved by the ethical committees of the 
participating centres. Of the 116 volunteers creened, 
three men and one woman were anti-HBs- and 
anti-HBc-positive, and these four were excluded. The 
remaining 112 volunteers were included in the study. 
Participants were randomized by order of entry in fixed 
blocks of six. A vaccine dose of 10pg (scheme A) 
yeast-derived recombinant HBsAg (Engerix-B) was given 
to 56 subjects and a dose of 20 pg (scheme B) was given 
to the remaining 56 by intramuscular injection in the 
deltoid region. There were no significant differences 
between groups with regard to age, sex, setting, daily 
amount of alcohol consumed or number of current 
prescriptions. Injections were given at 0, 1 and 6 months. 
Blood was drawn from an antecubital vein for anti-HBs 
measurement by radioimmunoassay (Ausab, Abbott 
Laboratories, Chicago, IL, USA; using a WHO standard) 
at 2, 6 and 7 months. Five persons withdrew before 
completion of the study, three in scheme A and two in 
scheme B, one because of a rise in his insulin requirement 
and the others for non-medical reasons. No other 
side-effects of vaccination were noted. Three anti-HBs 
titres at 2 months are missing in the remaining 107 
patients, two in scheme A and one in scheme B. By 
interpolation, the two missing values in scheme A can be 
assumed to equal zero. No anti-HBs titre at 7 months is 
available for one patient in scheme A. In the statistical 
analysis, actuarial (Kaplan-Meier) response rates for the 
total group of 112 participants and absolute response 
rates for the 106 subjects who had anti-HBs measured 
at 7 months were almost identical. In this report, only 
absolute numbers will be considered. Non-parametric 
tests (Fisher and Mann- Whitney) were used for the 
comparison of groups. Logistic regression analysis was 
used for multivariate testing of the effects on response 
rate. In a study of 112 patients at ~=0.05 and fl=0.10, 
differences of <30% between two groups may go 
undetected. 
RESULTS 
An anti-HBs titre ~> 10 IU 1-1 at 7 months was found in 
30 out of 52 subjects in scheme A (58%, 95% confidence 
interval (CI): 45-71%) and in 34 out of 54 in scheme B 
(63%, 95% CI: 50-76%). At two months, these figures 
were 12 and 9%, respectively, and at 6 months they were 
27 and 24%, respectively (Figure 1). These differences 
between scheme A and scheme B are not significant 
(t7 > 0.05, Fisher test). The anti-HBs titres in responders 
(~>10IU1-1) at 2, 6 and 7 months (Table2) also fail to 
show significant differences between scheme A and 
scheme B (p > 0.05, Mann-Whitney test), The geometric 
mean titre at 7 months was 253 IU 1-1 for the total group. 
Univariate testing of differences between responders 
and non-responders (Table 3) yielded no significance for 
sex, vaccine dose, daily amount of alcohol consumed or 
age. Significant differences were found for the setting of 
the vaccination trial (in or out of hospital, p = 0.049) and 
for the use of medication at the time of the first 
vaccination (p=0.001). Multivariate logistic regression 
analysis hows that the use of medication at the time of 
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Figure 1 Response to vaccination with (A) 10pg or (B) 20/tg 
yeast-derived recombinant HBsAg in elderly volunteers at different 
times: (~1) anti-HBs >10001U1-1; ([]) anti-HBs >1001U1-1; (Cq) 
anti-HBs >10 IU 1-1 
Table 2 Anti-HBs titres in responders (anti-HBs >~101U1-1) to 
vaccination with 10 or 20/tg yeast-derived recombinant HBsAg at 
different imes after first vaccination 
Anti-HBs 
Months geometric Anti-HBs 
after first Vaccine Number of mean titre range 
vaccination dose responders (IU 1-1) (IU 1-1) pa 
2 10 6 35 11-473"~ 
20 5 20 10-65 ( J 0,58 
6 10 14 30 13-93 "{ 
20 13 33 10-131J 0.72 
7 10 30 203 10-6720 "1 
20 34 308 12-13 736J 0.44 
aMann-Whitney test 
Vaccine 1994 Vo lume 12 Number  6 533 
Immunogenicity of rHBsAg vaccine in elderly subjects: S. de Rave et al. 
Table 3 Comparison of entry characteristics in responders (anti-HBs 
~>101U1-1) and non-responders to vaccination with yeast-derived 
recombinant HBsAg using univariate tests 
Responders Non-responders p 
Sex (male/female) 36/28 24/18 1.00 a 
Vaccine dose (10/~g/20 #g) 30/34 22/20 0.69 a 
Alcohol (ml day- l :  median, 0, 0-10 0, 0-20 0.378 
range) 
Age (years: median, range) 67, 61-79 68, 59-81 0.31 b 
In/out of hospital 42/22 35/7 0.049 a 
Medication (yes/no) 26/38 31/11 0.001 a 
"Fisher test 
bMann-Whitney test 
the first vaccination is the only independent factor elated 
to presence or absence of an anti-HBs response 
~> 10 IU 1-1 after 7 months (p =0.001). 
D ISCUSSION 
The present study clearly shows that the response rate 
in elderly volunteers vaccinated with yeast-derived 
rHBsAg (60%, 95% CI: 51-70%) was below that 
expected for healthy adolescents. For 870 healthy 
volunteers below the age of 40 years, a response rate of 
99.5% (95% CI: 99.1-100%) has been reported after a 
vaccination course identical to that in our study 1. In a 
study in 141 newborns 8 conducted at the same time with 
the same vaccine, a 100% response to vaccination was 
found, which makes technical f aws related to the vaccine 
or to the antibody measurements an unlikely reason for 
our finding of low responsiveness. 
Contrary to our expectations, we found no differences 
between the 10/~g and the 20 #g doses. The only factor 
with a negative influence on the response rate in our 
study was the use of medication at the time of the first 
vaccination. The response rate was 78% (95% CI: 
6689%)  in the group without medication compared with 
46% (95% CI: 33-59%) in the group using one or more 
prescriptions. The use of medication may reflect poorer 
general health in the latter group. Even in the subjects 
without medication, the response rate was below that 
reported for younger age groups. Within the group 
studied here, we found no relationship between age and 
response to vaccination, contrary to the report by Denis 
et al. 3. Their study does not mention the use of 
medication by the vaccinees, which may be an alternative 
explanation for the difference found between their age 
categories. 
In conclusion, age appears to be a very important 
factor in the immune response to recombinant HBsAg, 
even though our study did not include a younger control 
group. Within the group of elderly volunteers, the 
response to vaccination with yeast-derived recombinant 
HBsAg is further influenced by general health as reflected 
by the use of medication. 
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